TQB-2618 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This TQB-2618 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether TQB-2618 can convert its Monoclonal antibody profile and TIM3 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | TQB-2618 (query alias: TQB-2618) |
|---|---|
| Modality / target | Monoclonal antibody; TIM3; TIM3 inhibitors |
| Highest global status | Phase 2 |
| Originator | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Active developers | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
The MCP disease footprint includes Nasopharyngeal Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Colorectal Adenocarcinoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| CTR20233217 | Phase 1 | Terminated | 75 | Primary endpoint not disclosed in English source |
| NCT06010901 | Phase 1 | Recruiting | 75 | Primary endpoint not disclosed in English source |
| NCT05975645 | Phase 1 | Terminated | 29 | Primary endpoint not disclosed in English source |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Anti-TIM-3 antibody TQB2618 in combination with penpulimab in relapsed or refractory classic Hodgkin lymphoma previously treated with PD-1/PD-L1 therapy: a multicenter, open-label, single-arm, phase Ib clinical trial
Phase 1; n=21; evaluation: Positive. Reported fields: ORR = 52.0 %
Combination of Tim-3 blockade TQB2618 with penpulimab and chemotherapy in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): A multicenter, single-arm, two-cohort, phase 2 study.
Phase 2; n=30; evaluation: Positive. Reported fields: mPFS = 10.8 Month ( 9.6 - 16.4)
153P - Combination of Tim-3 blockade TQB2618 with PD-1 blockade for patients with immunotherapy-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): Preliminary results from a phase II study
Phase 2; n=17; evaluation: Negative. Reported fields: AE = 76.5 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
TQB-2618 addresses Nasopharyngeal Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Colorectal Adenocarcinoma. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The MCP screen returned 9 matched transaction record(s) under the scope “target-level comparable: TIM3.” Partner activity is a market-validation signal, but it does not establish net present value.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: TIM3 records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-02-04 | Agenus received formal notice from Incyte electing to terminate the License, Development, and Commercialization Agreement | Phase 2 | US$25.0M upfront; US$510.0M milestones |
| 2024-05-06 | Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement | Phase 2 | US$75.0M upfront |
| 2020-11-27 | Harvard University to assess Peptron's PT-320 in treating Alzheimer's disease. | Preclinical | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Combinations of par2 inhibitors and immune checkpoint inhibitors for the treatment of cancer”. The milestone feed surfaced a patent-application signal described as “Pharmaceutical composition comprising human hyaluronidase PH20 and drug”. The milestone feed surfaced a patent-application signal described as “Improved treatments for advanced/metastatic cancers with checkpoint inhibitor resistance or resistance susceptibility”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.
7. Principal risks and diligence gates
- Clinical differentiation versus current standards and pipeline competitors
- Safety, dose optimization, and long-term tolerability
- Patent scope, territorial rights, manufacturing, and commercial positioning
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 2026-09-18. Counts and status fields may change as source records update.
